Compare VanEck Gold Miners ETF (GDX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Gold Miners ETF vs Medpace Holdings Inc — how do they compare? VanEck Gold Miners ETF trades at $91.24, while Medpace Holdings Inc trades at $600.16 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| GDX | MEDP | |
|---|---|---|
52-Week High | $115.84 | $620.59 |
52-Week Low | $56.60 | $393.42 |
Market Cap | — | $16.90B |
Sector | — | Technology |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDX trades at $90.92, up 0.48% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights institutional repositioning and strong gold price momentum driving miner performance. The ETF offers diversified exposure to gold mining equities, though key valuation ratios are not publicly detailed for the fund itself.
The outlook is supported by gold's rally and potential for miner catch-up, but risks include gold price volatility and sector underperformance relative to bullion. Analyst sentiment is mixed, with some seeing value in miners after recent gains, while technical indicators warn of near-term overextension.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
